BR112013000867A2 - composto de purina seletivos para delta p110 de pi3k e métodos de uso. - Google Patents
composto de purina seletivos para delta p110 de pi3k e métodos de uso.Info
- Publication number
- BR112013000867A2 BR112013000867A2 BR112013000867A BR112013000867A BR112013000867A2 BR 112013000867 A2 BR112013000867 A2 BR 112013000867A2 BR 112013000867 A BR112013000867 A BR 112013000867A BR 112013000867 A BR112013000867 A BR 112013000867A BR 112013000867 A2 BR112013000867 A2 BR 112013000867A2
- Authority
- BR
- Brazil
- Prior art keywords
- delta
- pi3k
- methods
- purine compound
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composto de purina seletivos para delta p110 de pi3k e métodos de uso. a invenção provê compostos que tem a fórmula geral: e estereoisômeros, tautômeros ou sai aceitos farmaceuticamente desses, em que r^1^,r^2^,r^3^,r^4^ e n são definidos aqui, composições incluindo os compostos e método de utilizar os compostos para tratar uma doença ou distúrbio mediado pelo isoforma delta de p110 de quinase pi3 selecionado de distúrbios imunológicos, câncer, doenças cardiovasculares, infecção viral, inflamação,distúrbios de funções de metabolismo/endócrinas e distúrbios neurológicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36432410P | 2010-07-14 | 2010-07-14 | |
PCT/EP2011/061930 WO2012007493A1 (en) | 2010-07-14 | 2011-07-13 | Purine compounds selective for ρi3κ p110 delta, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013000867A2 true BR112013000867A2 (pt) | 2016-05-17 |
Family
ID=44532789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013000867A BR112013000867A2 (pt) | 2010-07-14 | 2011-07-13 | composto de purina seletivos para delta p110 de pi3k e métodos de uso. |
Country Status (11)
Country | Link |
---|---|
US (1) | US8293736B2 (pt) |
EP (1) | EP2593455B1 (pt) |
JP (1) | JP5555378B2 (pt) |
KR (1) | KR101531117B1 (pt) |
CN (1) | CN103003279B (pt) |
BR (1) | BR112013000867A2 (pt) |
CA (1) | CA2802808A1 (pt) |
ES (1) | ES2536780T3 (pt) |
MX (1) | MX2013000389A (pt) |
RU (1) | RU2013104038A (pt) |
WO (1) | WO2012007493A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011521968A (ja) * | 2008-05-30 | 2011-07-28 | ジェネンテック, インコーポレイテッド | プリンpi3k阻害剤化合物および使用方法 |
CN102711766B (zh) * | 2009-11-12 | 2014-06-04 | 霍夫曼-拉罗奇有限公司 | N-9-取代的嘌呤化合物、组合物和使用方法 |
CA2820078C (en) | 2010-12-16 | 2019-02-12 | F. Hoffmann-La Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
US9949979B2 (en) | 2011-12-15 | 2018-04-24 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
RU2663999C2 (ru) | 2013-10-16 | 2018-08-14 | Шанхай Инли Фармасьютикал Ко., Лтд | Конденсированное гетероциклическое соединение, способ его получения, его фармацевтическая композиция и применения |
WO2015188369A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
WO2016064957A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
US10023576B2 (en) | 2014-10-22 | 2018-07-17 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors |
CA2980517C (en) | 2015-03-30 | 2020-02-25 | Daiichi Sankyo Company, Limited | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors |
GB201514751D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
TW201817731A (zh) * | 2016-09-29 | 2018-05-16 | 日商第一三共股份有限公司 | [2-(1-甲基-1h-吡唑-4-基)-6-( 啉-4-基)-9h-嘌呤-8-基][4-( 啉-4-基)哌啶-1-基]甲酮及其製藥上容許鹽之結晶 |
KR102399639B1 (ko) | 2016-12-02 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
JP7358890B2 (ja) | 2019-10-01 | 2023-10-11 | 富士フイルムビジネスイノベーション株式会社 | 物体質感計測装置 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3016378A (en) | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
US4782137A (en) | 1984-01-24 | 1988-11-01 | Immunex Corporation | Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
DE3406533A1 (de) | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
DE60144322D1 (de) | 2000-04-27 | 2011-05-12 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
AU2002323475B2 (en) | 2001-09-13 | 2006-09-28 | Synta Pharmaceuticals Corp | 2-aroylimidazole compounds for treating cancer |
EP1578722A4 (en) | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US20050288503A1 (en) | 2002-09-06 | 2005-12-29 | Adams Jerry L | Novel compounds |
JP4768265B2 (ja) * | 2002-10-15 | 2011-09-07 | シンタ ファーマシューティカルズ コーポレーション | 新規化合物 |
CA2527079A1 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
AU2005245875C1 (en) | 2004-05-13 | 2017-08-31 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
BRPI0617165B1 (pt) | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
AR060632A1 (es) | 2006-04-26 | 2008-07-02 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso |
AR060631A1 (es) * | 2006-04-26 | 2008-07-02 | Piramed Ltd | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) |
AR063142A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
CN101675053B (zh) | 2006-12-07 | 2014-03-12 | 健泰科生物技术公司 | 磷酸肌醇3-激酶抑制剂化合物及使用方法 |
JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
WO2008116911A1 (en) | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
CA2692050A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
JP5736171B2 (ja) * | 2007-09-24 | 2015-06-17 | ジェネンテック, インコーポレイテッド | チアゾロピリミジンpi3k阻害剤化合物および使用方法 |
EP2209785A1 (en) * | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
WO2009053716A1 (en) * | 2007-10-26 | 2009-04-30 | F.Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
ES2494365T3 (es) * | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
JP2011521968A (ja) | 2008-05-30 | 2011-07-28 | ジェネンテック, インコーポレイテッド | プリンpi3k阻害剤化合物および使用方法 |
AU2009269087A1 (en) * | 2008-07-07 | 2010-01-14 | Xcovery Holding Company Llc | PI3K isoform selective inhibitors |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
SG174527A1 (en) * | 2009-03-27 | 2011-11-28 | Pathway Therapeutics Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
CA2761445A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
AR080945A1 (es) * | 2009-07-07 | 2012-05-23 | Pathway Therapeutics Inc | Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer |
-
2011
- 2011-07-13 ES ES11736322.6T patent/ES2536780T3/es active Active
- 2011-07-13 RU RU2013104038/04A patent/RU2013104038A/ru not_active Application Discontinuation
- 2011-07-13 BR BR112013000867A patent/BR112013000867A2/pt not_active IP Right Cessation
- 2011-07-13 CA CA2802808A patent/CA2802808A1/en not_active Abandoned
- 2011-07-13 MX MX2013000389A patent/MX2013000389A/es active IP Right Grant
- 2011-07-13 EP EP11736322.6A patent/EP2593455B1/en not_active Not-in-force
- 2011-07-13 JP JP2013519085A patent/JP5555378B2/ja not_active Expired - Fee Related
- 2011-07-13 WO PCT/EP2011/061930 patent/WO2012007493A1/en active Application Filing
- 2011-07-13 KR KR1020137003606A patent/KR101531117B1/ko not_active IP Right Cessation
- 2011-07-13 CN CN201180034691.1A patent/CN103003279B/zh not_active Expired - Fee Related
- 2011-07-13 US US13/181,647 patent/US8293736B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20130038921A (ko) | 2013-04-18 |
WO2012007493A1 (en) | 2012-01-19 |
EP2593455A1 (en) | 2013-05-22 |
CA2802808A1 (en) | 2012-01-19 |
US8293736B2 (en) | 2012-10-23 |
CN103003279B (zh) | 2015-09-23 |
EP2593455B1 (en) | 2015-03-18 |
JP2013531022A (ja) | 2013-08-01 |
CN103003279A (zh) | 2013-03-27 |
MX2013000389A (es) | 2013-03-08 |
JP5555378B2 (ja) | 2014-07-23 |
US20120015931A1 (en) | 2012-01-19 |
ES2536780T3 (es) | 2015-05-28 |
KR101531117B1 (ko) | 2015-06-23 |
RU2013104038A (ru) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013000867A2 (pt) | composto de purina seletivos para delta p110 de pi3k e métodos de uso. | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
MX340013B (es) | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. | |
MX2009010881A (es) | Compuestos farmaceuticos. | |
IL201365A0 (en) | Pyrimidine derivatives as inhibitors of phosphatidylinositol - 3 kinase | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
NO20084931L (no) | Farmasoytiske sammensetninger | |
MX2009002171A (es) | Derivados de triazol como inhibidores de cinasas. | |
MX346336B (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
NZ612909A (en) | Processes for preparing isoquinolinones and solid forms of isoquinolinones | |
EA201590624A1 (ru) | Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения | |
MX2011012520A (es) | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. | |
WO2009132202A3 (en) | Macrocyclic compounds and their use as kinase inhibitors | |
MX2010004705A (es) | Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7. | |
EA201290305A1 (ru) | Производные трициклического пиразоламина | |
WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
WO2008060621A3 (en) | Aminopyrrolidines as chemokine receptor antagonists | |
MX2010005700A (es) | Amino triazoles como inhibidores pi3k. | |
BR112015026721A2 (pt) | derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer | |
WO2013038429A3 (en) | Novel sglt inhibitors | |
WO2012101654A3 (en) | Novel triazine compounds | |
NO20085257L (no) | Purinonderivater som HM74a-agonister | |
EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
MX2009009154A (es) | Derivados de espiro-pirano-pirazol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |